Although these hard-to-treat cancers can’t be completely eradicated, 177Lu-PSMA therapy aims to reduce the size and progress of the cancer, ease symptoms and, in doing so, maintain or improve quality of life (Weineisen et al., 2015; Plichta et al., 2021). This evidence concerns the gene FOLH1 and cancer.